Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
ACIS assessment of HER-2/neu expression fast, accurate, and cost-effective
March 9th, 2006
Assessment of HER-2/neu expression in breast tumors using the ACIS system (ChromaVision Medical Systems, Inc., San Juan Capistrano, CA) is fast, accurate, and cost-effective. "Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer," pathologists in the United States explained. "However, there is still no consensus on which method is most predictive of patient response to Herceptin." "Recently, the automated cellular imaging system (ACIS) has been shown to improve the accuracy and reproducibility in scoring IHC," noted O.W. Tawfik and...
Source: Women's Health Weekly (2006-03-09)
|
